PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2104796-2	1990	Rioprostil administration, 300 micrograms twice daily resulted in a significant decrease of fasting insulin, C-peptide, glucagon, and pancreatic polypeptide.	Rioprostil	0-10	insulin	Homo sapiens	100-107	
2104796-6	1990	Treatment with rioprostil remained without effect on mixed meal-induced changes in plasma glucose levels and concomitant increases in insulin, pancreatic polypeptide, and somatostatin levels.	Rioprostil	15-25	insulin	Homo sapiens	134-141	
2104796-7	1990	It is concluded that in healthy individuals rioprostil influences the basal and glucose-induced levels of glucagon, insulin, and somatostatin.	Rioprostil	44-54	insulin	Homo sapiens	116-123	
2510253-4	1989	They also reduce the maximal postprandial insulin concentration, but only rioprostil (600 micrograms) reduces the 3-h integrated release of insulin significantly (by approximately 20%).	Rioprostil	74-84	insulin	Homo sapiens	140-147	
2510253-9	1989	In conclusion, rioprostil given with a meal can reduce the insulin release but it does not change the postprandial blood glucose levels when given as a single dose or repeatedly in an evening dose.	Rioprostil	15-25	insulin	Homo sapiens	59-66	
2509214-4	1989	Misoprostol and rioprostil reduced integrated incremental responses of GIP by 57% (P less than or equal to 0.001) and 45% (P less than or equal to 0.01), respectively, and both gave rise to an initial (approximately 10 min) delay of insulin and C-peptide responses, without a significant overall reduction in integrated incremental responses.	Rioprostil	16-26	insulin	Homo sapiens	245-254